Published in Liver Transpl on January 01, 2005
Living donor liver transplantation for an adult patient with situs inversus totalis. World J Gastroenterol (2010) 0.91
Liver transplantation using a graft from a donor with situs inversus totalis: a case report and review of the literature. Case Rep Transplant (2013) 0.84
Living donor liver transplantation in an adult patient with situs inversus totalis. Ulus Cerrahi Derg (2015) 0.75
Recurrence of cholestatic liver disease after living donor liver transplantation. World J Gastroenterol (2008) 0.75
Primary sclerosing cholangitis as an intractable disease. Intractable Rare Dis Res (2012) 0.75
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol (2005) 4.65
Acute liver failure: Summary of a workshop. Hepatology (2008) 3.49
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology (2005) 2.99
EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc (2007) 2.61
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology (2010) 2.55
Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol (2006) 2.48
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol (2011) 2.38
Non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2002) 2.32
Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23
Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg (2009) 2.23
Anesthetic, patient, and surgical risk factors for neurologic complications after prolonged total tourniquet time during total knee arthroplasty. Anesth Analg (2006) 2.16
Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology (2005) 2.15
Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol (2004) 2.11
Nonalcoholic fatty liver disease. Ann Epidemiol (2007) 2.09
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology (2004) 2.09
Enhanced recovery in gynecologic surgery. Obstet Gynecol (2013) 2.07
Gender differences in academic productivity and leadership appointments of physicians throughout academic careers. Acad Med (2011) 2.03
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology (2006) 1.93
The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol (2004) 1.92
Primary biliary cirrhosis. Lancet (2003) 1.90
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology (2009) 1.90
Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant (2004) 1.87
Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg (2004) 1.79
Chronic renal dysfunction late after liver transplantation. Liver Transpl (2002) 1.74
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70
A recipient risk score for deceased donor renal allocation. Am J Kidney Dis (2007) 1.70
Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology (2002) 1.69
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl (2007) 1.69
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol (2003) 1.68
Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int (2009) 1.68
Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis (2011) 1.68
Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol (2004) 1.65
Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl (2007) 1.64
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Primary sclerosing cholangitis. Lancet (2013) 1.59
Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol (2002) 1.58
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.56
Gastric diverticulum: a series of four pediatric patients. J Pediatr Gastroenterol Nutr (2002) 1.54
Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford) (2011) 1.54
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant (2011) 1.51
Hepatopulmonary syndrome: favorable outcomes in the MELD exception era. Hepatology (2013) 1.50
Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol (2005) 1.48
Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl (2004) 1.47
Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol (2003) 1.47
Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation (2009) 1.47
Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis (2007) 1.46
Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology (2008) 1.45
Research productivity of graduates from 3 physician-scientist training programs. Am J Med (2008) 1.44
Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation (2006) 1.43
The value of observational research in liver diseases. Hepatology (2011) 1.43
Utility of liver biopsy in bone marrow transplant patients. J Gastroenterol Hepatol (2008) 1.41
Rat hepatocyte spheroids formed by rocked technique maintain differentiated hepatocyte gene expression and function. Hepatology (2009) 1.41
Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology (2007) 1.39
Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis (2004) 1.34
MELD and other factors associated with survival after liver transplantation. Am J Transplant (2004) 1.34
Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology (2004) 1.33
Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant (2003) 1.29
Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation (2004) 1.29
Ultrasound-assisted percutaneous liver biopsy performed by a physician assistant. Am J Gastroenterol (2002) 1.29
Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl (2004) 1.29
Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol (2004) 1.24
Cell therapies for liver diseases. Liver Transpl (2012) 1.24
Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res (2011) 1.23
IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol (2010) 1.22
Artificial and bioartificial liver support. Semin Liver Dis (2008) 1.21
Obesity in living kidney donors: clinical characteristics and outcomes in the era of laparoscopic donor nephrectomy. Am J Transplant (2005) 1.20
Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology (2002) 1.20
Assessment of donor liver steatosis: pathologist or automated software? Hum Pathol (2004) 1.17
Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol (2010) 1.17
Primary sclerosing cholangitis. Can J Gastroenterol (2008) 1.17
Bone disease in patients with primary sclerosing cholangitis. Gastroenterology (2010) 1.15
The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int (2012) 1.15
Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatol (2002) 1.14
Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol (2006) 1.13
Improved scoring system to assess adult donors for cadaver renal transplantation. Am J Transplant (2003) 1.13
The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol (2007) 1.13
Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol (2011) 1.12
Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol (2003) 1.10
Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol (2005) 1.10
Portal hypertension correlates with splenic stiffness as measured with MR elastography. J Magn Reson Imaging (2011) 1.10
Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents. Clin Liver Dis (2008) 1.09
Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival. Liver Transpl (2006) 1.09
Endoscopic retrograde cholangiography in post-orthotopic liver transplant population with Roux-en-Y biliary reconstruction. Liver Transpl (2007) 1.09
Treatment options for hepatobiliary and pancreatic cancer. Mayo Clin Proc (2007) 1.08